Skip to main content
SP5007,680.94+0.05%DOW53,487.78-0.17%NASDAQ26,122.93-0.11%BTC$78,059.00-1.56%ETH$2,449.61-0.96%GOLD$4,657.50-0.79%OIL$82.28-0.10%
Smart Investors Daily
Sign InSign Up Free
GN

OTC · GNFTY

Genfit S.A.

Healthcare · Biotechnology

$8.95

Up+$0.00 (+0.00%)

Updated Aug 26, 2026, 3:29 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
293.15M
P/E ratio
166.5
Dividend yield
100.33%
52-week range
— – —
Volume
1.61K
Avg. volume
9.93K

Price performance

GNFTY price history

1M range · 0 trading sessions · Daily adjusted prices

GNFTY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest GNFTY news

The latest Smart Investors Daily articles mentioning GNFTY.

Stock researchCompany · Overview

GNFTY research

Overview

Company profile and research snapshot.

Company profile

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
GNFTY recent ratings
DateFirmRatingTarget
Jul 2, 2026ODDO BHFBuy—
Jun 28, 2026PORTZAMPARC BNP PARIBASBuy—
Jun 17, 2026ESN/CIC MARKET SOLUTIONSBuy—
Mar 15, 2026LEERINK PARTNERSOutperform—
Feb 27, 2026ODDO BHFBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 13, 2026

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 13, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31,

Yahoo · Jan 7, 2026

GENFIT Announces 2026 Financial Calendar

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026. 2026 Financial Calendar February 26, 2026Publication of revenue and cash position at December 31, 2025April 2, 2026Publication of Full Year 2025 financial statements The 2025 Universal

Yahoo · Jan 6, 2026

GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N

Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluationCompelling anti-inflammatory activity of G1090N was evidenced through functional ex vivo assays on blood samples from study participants and cirrhotic donors, showing inhibition of pro-inflammatory pathwayFindings provide a solid foundation for advancing G1090N into Phase 2 proof-of-concept studies across the ACLF continuum Lille (France), Cambridge

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By